Colorcon Adds Lab in Beijing
Colorcon expands its presence in China with a technical service center to serve the northern region.
Colorcon has announced that the company opened a new technical service laboratory in Beijing, China on June 25. Located in the Beijing YiZhuang Biomedical Park, the technical center is the company’s second facility in China and 19th worldwide.
Equipped for research-scale solid dose development, the laboratory support the development and commercialization pharmaceutical drug formulations from initial product concept, to pilot scale trials through to final production and registration.
The company established Shanghai Colorcon Coating Technology Limited in 1993 and made additional strategic investments in China in a supply chain and the local manufacture of Opadry film coatings.
Source: Colorcon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
